Optimizing doses and biomarkers in early-phase trials to inform Phase III dose and population decisions is a priority at AstraZeneca. Statistical approaches to address dose optimization and consideration of the population are needed. Adaptive design, Bayesian analysis, statistical modelling and utility-based approaches will be an important component of this project. The overall objective for this position will be to identify trial design and analysis methods to advance the goals of dose optimization and integrate biomarker optimization. The postdoc will join our collaborative and supportive DOWGS (Dose Optimization Working Group Statistical Innovation) group and SIMBA (Statistical Innovation Meets BiomArker discovery) group, supervised by Dr. Gina D’Angelo. They will also have close interactions with scientists of various backgrounds, including statisticians, data scientists, clinicians, regulatory, and precision medicine. Project Focus The project will begin with a critical evaluation of existing approaches. Subsequent methodological work will focus on dose-optimization approaches evaluating utility-based approaches, missing data approaches, pooling multiple sources of data including data from other trials, jointly optimizing the dose and biomarker, and trial design. The postdoc will be responsible for writing scientific papers, presenting talks and supporting the scientific development of statistical methodology at AstraZeneca.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
Ph.D. or professional degree